Valeo Pharma Inc - ESG Rating & Company Profile powered by AI
Browse to the end of this page for potential risks for Valeo Pharma Inc based on industry, geography and size. This assessment of Valeo Pharma Inc is prepared by All Street Sevva using proprietary artificial intelligence. If you are employed by Valeo Pharma Inc and you would like to licence your ESG aseessment, please get in touch.
Valeo Pharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 8.0, social score of 8.0 and governance score of 5.3.
7.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 217 | Takara Bio Inc | 7.2 | High |
| 217 | Ultragenyx Pharmaceutical Inc | 7.2 | High |
| 224 | Valeo Pharma Inc | 7.1 | High |
| 224 | Celularity Inc | 7.1 | High |
| 224 | Bilcare Ltd | 7.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Valeo Pharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Valeo Pharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Valeo Pharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Valeo Pharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Valeo Pharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Valeo Pharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Valeo Pharma Inc offer flexible work?
Sign up for free to unlockDoes Valeo Pharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Valeo Pharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Valeo Pharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Valeo Pharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Valeo Pharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Valeo Pharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Valeo Pharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Valeo Pharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Valeo Pharma Inc disclose water use targets?
Sign up for free to unlockDoes Valeo Pharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Valeo Pharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Valeo Pharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Valeo Pharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Valeo Pharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Valeo Pharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Valeo Pharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Valeo Pharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Valeo Pharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Valeo Pharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Valeo Pharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Valeo Pharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Valeo Pharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Valeo Pharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Valeo Pharma Inc disclose its waste policy?
Sign up for free to unlockDoes Valeo Pharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Valeo Pharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Valeo Pharma Inc disclose energy use targets?
Sign up for free to unlockDoes Valeo Pharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Valeo Pharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Valeo Pharma Inc
These potential risks are based on the size, segment and geographies of the company.
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.